People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Pharmaceuticals, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $494.8M | 2016 |
| Nuvation Bio Inc. | — | Pharmaceuticals | Series D+ | $275.3M | $9.7B | 2019 |
| Alveus Therapeutics, Inc. | — | Pharmaceuticals | Series C | $56.9M | $297.8M | 2025 |
| Avitide, Inc. | — | Pharmaceuticals | Series A | $40.9M | $309.7M | 2015 |
| Spiro Medical Inc. | — | Healthtech | Series B | $39.1M | $156.5M | 2025 |
Claudio Nessi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Claudio Nessi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 2 | 18 |
| Tillman Gerngross | 2 | 5 |
| Carl Gordon | 1 | 24 |
| Ajay Royan | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Terrance McGuire | 1 | 9 |
| Errik Anderson | 1 | 8 |
| CARL L. GORDON | 1 | 7 |
| Philip Ferneau | 1 | 6 |
| Ian Ratcliffe | 1 | 6 |
| Michael Gray | 1 | 6 |
| Michael Wyzga | 1 | 5 |
| Errik B. Anderson | 1 | 5 |
| Tillman U. Gerngross | 1 | 5 |
| Robert L. Birnbaum | 1 | 4 |
| William Aliski | 1 | 4 |
| Daniel Burgess | 1 | 4 |
| Michael L. Ross | 1 | 3 |
| Kim Blickenstaff | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.